The goal of research at LIBD is to identify new strategies to change the lives of individuals affected by schizophrenia and related developmental disorders.
From genes to drugs
Rather than focusing on disease specific molecules, our drug development program has identified targets with much broader clinical application, focusing on chemicals involved in “tuning” human cortical function to improve cognition and modulate impulse control across many conditions where these capacities are compromised. Through investigation of these innovative targets, our scientists are validating new approaches that will ultimately lead to novel treatments.
In six years of operations, we have made considerable progress in identifying and developing a promising set of novel therapeutic targets including two that could be in clinical trials within two to three years. In addition, we have four promising leads that could introduce two new drugs into Phase II clinical trials by 2021.
Our state-of-the-art laboratory space is located on the Johns Hopkins Medical Campus. LIBD is the largest non-Johns Hopkins University employer of the East Baltimore inner-city development project.
LIBD Speaker Series: Dara S. Manoach, Ph.D.
Reduced Sleep Spindles in Schizophrenia: A Treatable Endophenotype that Links Risk Genes to Impaired Cognition Dara S. Manoach, Ph.D. Professor of Psychology, Department of Psychiatry Massachusetts General Hospital, Harvard Medical School Athinoula A. Martinos Center for Biomedical Imaging When: August […]